{"id":79171,"date":"2026-09-07T12:05:51","date_gmt":"2026-09-07T04:05:51","guid":{"rendered":"https:\/\/flcube.com\/?p=79171"},"modified":"2026-09-07T12:05:52","modified_gmt":"2026-09-07T04:05:52","slug":"tennor-therapeutics-reports-positive-phase-iia-top-line-results-for-tnp-2092-in-prosthetic-joint-infection-first-in-class-triple-target-candidate-advances-to-p","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=79171","title":{"rendered":"TenNor Therapeutics Reports Positive Phase IIa Top\u2011Line Results for TNP\u20112092 in Prosthetic Joint Infection; First\u2011in\u2011Class Triple\u2011Target Candidate Advances to Phase IIb"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>TenNor Therapeutics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/6872:HKG\">HKG: 6872<\/a>) today announced positive top\u2011line results from its Phase IIa proof\u2011of\u2011concept clinical trial evaluating <strong>TNP\u20112092<\/strong>, its investigational first\u2011in\u2011class drug candidate administered via intra\u2011articular injection for the treatment of <strong>prosthetic joint infection (PJI)<\/strong>. Building on these findings, the company has recently initiated a multi\u2011center Phase IIb clinical trial.<\/p>\n\n\n\n<h2 id=\"h-clinical-milestone\" class=\"wp-block-heading\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Field<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Company<\/td><td><strong>TenNor Therapeutics<\/strong> (HKG: 6872)<\/td><\/tr><tr><td>Product<\/td><td><strong>TNP\u20112092<\/strong> (investigational, first\u2011in\u2011class)<\/td><\/tr><tr><td>Route of Administration<\/td><td>Intra\u2011articular injection<\/td><\/tr><tr><td>Indication<\/td><td><strong>Prosthetic joint infection (PJI)<\/strong> \/ medical device\u2011implant infections<\/td><\/tr><tr><td>Trial Stage<\/td><td>Phase IIa proof\u2011of\u2011concept \u2014 positive top\u2011line results<\/td><\/tr><tr><td>Date<\/td><td>07 Sep 2026<\/td><\/tr><tr><td>Next Steps<\/td><td>Multi\u2011center Phase IIb clinical trial recently initiated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>TNP\u20112092<\/strong>, a first\u2011in\u2011class investigational drug specifically developed for medical device\u2011implant infections.<\/li>\n\n\n\n<li><strong>Novel Mechanism:<\/strong> A three\u2011target mechanism of action with unique triple\u2011target synergy.<\/li>\n\n\n\n<li><strong>Targets:<\/strong> Simultaneously inhibits bacterial RNA polymerase, DNA gyrase, and topoisomerase IV.<\/li>\n\n\n\n<li><strong>Spectrum:<\/strong> Potent antibacterial activity against drug\u2011resistant pathogens, including <strong>methicillin\u2011resistant Staphylococcus aureus (MRSA)<\/strong> and <strong>quinolone\u2011resistant Staphylococcus aureus (QRSA)<\/strong>.<\/li>\n\n\n\n<li><strong>Resistance Profile:<\/strong> Significantly reduces resistance frequency to an extremely low level (&lt;10\u207b\u00b9\u00b2), a key differentiator in anti\u2011infective development.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-iia-proof-of-concept-trial\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase IIa Proof\u2011of\u2011Concept Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td>Design<\/td><td>Phase IIa proof\u2011of\u2011concept, intra\u2011articular administration<\/td><\/tr><tr><td>Population<\/td><td>Patients with <strong>prosthetic joint infection (PJI)<\/strong><\/td><\/tr><tr><td>Top\u2011Line Outcome<\/td><td>Positive<\/td><\/tr><tr><td>Follow\u2011On<\/td><td>Multi\u2011center Phase IIb trial recently initiated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The Phase IIa proof\u2011of\u2011concept readout marks the first clinical validation of the <strong>TNP\u20112092<\/strong> triple\u2011target approach in <strong>PJI<\/strong>, a serious complication of joint replacement surgery frequently driven by drug\u2011resistant staphylococcal pathogens. The company characterized the top\u2011line results as positive and moved directly into a multi\u2011center Phase IIb program, signaling confidence in the candidate&#8217;s clinical profile. Detailed efficacy and safety data were not included in the top\u2011line announcement.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> <strong>Prosthetic joint infection<\/strong> remains a challenging, often revision\u2011requiring complication of implant surgery, with limited dedicated therapeutic options \u2014 particularly against resistant organisms such as <strong>MRSA<\/strong> and <strong>QRSA<\/strong>.<\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class Positioning:<\/strong> As a candidate purpose\u2011built for medical device\u2011implant infections, <strong>TNP\u20112092<\/strong> differentiates from conventional antibiotics through its triple\u2011target synergy.<\/li>\n\n\n\n<li><strong>Resistance Advantage:<\/strong> The ultra\u2011low resistance frequency (&lt;10\u207b\u00b9\u00b2) addresses a core weakness of existing anti\u2011staphylococcal therapies and may support long\u2011term clinical utility.<\/li>\n\n\n\n<li><strong>Development Trajectory:<\/strong> Initiation of the multi\u2011center Phase IIb trial expands the evidence base and moves <strong>TenNor Therapeutics<\/strong> closer to a potential registration pathway.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding <strong>TenNor Therapeutics<\/strong>&#8216; development of <strong>TNP\u20112092<\/strong>, including the ongoing Phase IIb clinical trial and its potential for the treatment of <strong>prosthetic joint infection<\/strong>. Such statements are based on current expectations and are subject to risks and uncertainties, including clinical development, regulatory review, and commercialization risks. Actual results may differ materially. Nothing herein constitutes investment advice or an offer to buy or sell any securities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090700044_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026090700044_c.\"><\/object><a id=\"wp-block-file--media-2db16357-47d8-48d6-8419-e6e6589395c7\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090700044_c.pdf\">2026090700044_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090700044_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2db16357-47d8-48d6-8419-e6e6589395c7\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TenNor Therapeutics (HKG: 6872) today announced positive top\u2011line results from its Phase IIa proof\u2011of\u2011concept clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,4929,2192],"class_list":["post-79171","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hkg-6872","tag-tennor-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TenNor Therapeutics Reports Positive Phase IIa Top\u2011Line Results for TNP\u20112092 in Prosthetic Joint Infection; First\u2011in\u2011Class Triple\u2011Target Candidate Advances to Phase IIb - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TenNor Therapeutics (HKG: 6872) today announced positive top\u2011line results from its Phase IIa proof\u2011of\u2011concept clinical trial evaluating TNP\u20112092, its investigational first\u2011in\u2011class drug candidate administered via intra\u2011articular injection for the treatment of prosthetic joint infection (PJI). Building on these findings, the company has recently initiated a multi\u2011center Phase IIb clinical trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=79171\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TenNor Therapeutics Reports Positive Phase IIa Top\u2011Line Results for TNP\u20112092 in Prosthetic Joint Infection; First\u2011in\u2011Class Triple\u2011Target Candidate Advances to Phase IIb\" \/>\n<meta property=\"og:description\" content=\"TenNor Therapeutics (HKG: 6872) today announced positive top\u2011line results from its Phase IIa proof\u2011of\u2011concept clinical trial evaluating TNP\u20112092, its investigational first\u2011in\u2011class drug candidate administered via intra\u2011articular injection for the treatment of prosthetic joint infection (PJI). Building on these findings, the company has recently initiated a multi\u2011center Phase IIb clinical trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=79171\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-07T04:05:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-07T04:05:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79171#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79171\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TenNor Therapeutics Reports Positive Phase IIa Top\u2011Line Results for TNP\u20112092 in Prosthetic Joint Infection; First\u2011in\u2011Class Triple\u2011Target Candidate Advances to Phase IIb\",\"datePublished\":\"2026-09-07T04:05:51+00:00\",\"dateModified\":\"2026-09-07T04:05:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79171\"},\"wordCount\":514,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"HKG: 6872\",\"TenNor Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=79171#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79171\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=79171\",\"name\":\"TenNor Therapeutics Reports Positive Phase IIa Top\u2011Line Results for TNP\u20112092 in Prosthetic Joint Infection; First\u2011in\u2011Class Triple\u2011Target Candidate Advances to Phase IIb - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-07T04:05:51+00:00\",\"dateModified\":\"2026-09-07T04:05:52+00:00\",\"description\":\"TenNor Therapeutics (HKG: 6872) today announced positive top\u2011line results from its Phase IIa proof\u2011of\u2011concept clinical trial evaluating TNP\u20112092, its investigational first\u2011in\u2011class drug candidate administered via intra\u2011articular injection for the treatment of prosthetic joint infection (PJI). Building on these findings, the company has recently initiated a multi\u2011center Phase IIb clinical trial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79171#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=79171\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79171#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TenNor Therapeutics Reports Positive Phase IIa Top\u2011Line Results for TNP\u20112092 in Prosthetic Joint Infection; First\u2011in\u2011Class Triple\u2011Target Candidate Advances to Phase IIb\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TenNor Therapeutics Reports Positive Phase IIa Top\u2011Line Results for TNP\u20112092 in Prosthetic Joint Infection; First\u2011in\u2011Class Triple\u2011Target Candidate Advances to Phase IIb - Insight, China&#039;s Pharmaceutical Industry","description":"TenNor Therapeutics (HKG: 6872) today announced positive top\u2011line results from its Phase IIa proof\u2011of\u2011concept clinical trial evaluating TNP\u20112092, its investigational first\u2011in\u2011class drug candidate administered via intra\u2011articular injection for the treatment of prosthetic joint infection (PJI). Building on these findings, the company has recently initiated a multi\u2011center Phase IIb clinical trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=79171","og_locale":"en_US","og_type":"article","og_title":"TenNor Therapeutics Reports Positive Phase IIa Top\u2011Line Results for TNP\u20112092 in Prosthetic Joint Infection; First\u2011in\u2011Class Triple\u2011Target Candidate Advances to Phase IIb","og_description":"TenNor Therapeutics (HKG: 6872) today announced positive top\u2011line results from its Phase IIa proof\u2011of\u2011concept clinical trial evaluating TNP\u20112092, its investigational first\u2011in\u2011class drug candidate administered via intra\u2011articular injection for the treatment of prosthetic joint infection (PJI). Building on these findings, the company has recently initiated a multi\u2011center Phase IIb clinical trial.","og_url":"https:\/\/flcube.com\/?p=79171","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-07T04:05:51+00:00","article_modified_time":"2026-09-07T04:05:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=79171#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=79171"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TenNor Therapeutics Reports Positive Phase IIa Top\u2011Line Results for TNP\u20112092 in Prosthetic Joint Infection; First\u2011in\u2011Class Triple\u2011Target Candidate Advances to Phase IIb","datePublished":"2026-09-07T04:05:51+00:00","dateModified":"2026-09-07T04:05:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=79171"},"wordCount":514,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","HKG: 6872","TenNor Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=79171#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=79171","url":"https:\/\/flcube.com\/?p=79171","name":"TenNor Therapeutics Reports Positive Phase IIa Top\u2011Line Results for TNP\u20112092 in Prosthetic Joint Infection; First\u2011in\u2011Class Triple\u2011Target Candidate Advances to Phase IIb - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-07T04:05:51+00:00","dateModified":"2026-09-07T04:05:52+00:00","description":"TenNor Therapeutics (HKG: 6872) today announced positive top\u2011line results from its Phase IIa proof\u2011of\u2011concept clinical trial evaluating TNP\u20112092, its investigational first\u2011in\u2011class drug candidate administered via intra\u2011articular injection for the treatment of prosthetic joint infection (PJI). Building on these findings, the company has recently initiated a multi\u2011center Phase IIb clinical trial.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=79171#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=79171"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=79171#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TenNor Therapeutics Reports Positive Phase IIa Top\u2011Line Results for TNP\u20112092 in Prosthetic Joint Infection; First\u2011in\u2011Class Triple\u2011Target Candidate Advances to Phase IIb"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=79171"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79171\/revisions"}],"predecessor-version":[{"id":79176,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79171\/revisions\/79176"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=79171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=79171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=79171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}